Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2013 April;104(2) > Minerva Medica 2013 April;104(2):155-60

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

  THROMBOSIS


Minerva Medica 2013 April;104(2):155-60

language: English

Myeloma and thrombotic complications

Tzoran I. 1, Brenner B. 1, 2, Hoffman R. 1, 2

1 Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus, Haifa, Israel;
2 Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel


PDF  


Multiple myeloma (MM) is a hematological malignancy with high risk for thrombosis. While venous thromboembolism is more common, myeloma patients can also present with arterial thrombosis. Risk factors responsible for this complication can be patient-related, myeloma- and treatment-related. Thromboprophylaxis is indicated along with specific therapeutic regimens employed in myeloma patients. This review will cover potential risk factors for thrombosis in patients with multiple myeloma, prevention recommendations and treatment strategies in this clinical setting.

top of page

Publication History

Cite this article as

Corresponding author e-mail

b_brenner@rambam.health.gov.il